Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review.
ACE2
COVID-19
Immunotherapy
S protein
Vaccines
Journal
Iranian journal of public health
ISSN: 2251-6093
Titre abrégé: Iran J Public Health
Pays: Iran
ID NLM: 7505531
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
10
03
2020
accepted:
21
03
2020
entrez:
16
7
2021
pubmed:
17
7
2021
medline:
17
7
2021
Statut:
ppublish
Résumé
COVID-19 is considered as the third human coronavirus and has a high potential for transmission. Fast public health interventions through antibodies, anti-virals or novel vaccine strategies to control the virus and disease transmission have been extremely followed. SARS-CoV-2 shares about 79% genomic similarity with SARS-CoV and approximately 50% with MERS-CoV. Based on these similarities, prior knowledge in treating SARS-CoV and MERS-CoV can be used as the basis of majority of the alternatives for controlling SARS-CoV-2. Immunotherapy is an effective strategy for clinical treatment of infectious diseases such as SARS-CoV-2. Passive antibody therapy, which decreases the virus replication and disease severity, is assessed as an effective therapeutic approach to control SARS-CoV-2 epidemics. The close similarity between SARS-CoV-2 genome with the SARS-CoV genome caused both coronaviruses to bind to the same angiotensin-converting enzyme 2 (ACE2) receptors that found in the human lung. There are several strategies to develop SARS-CoV-2 vaccines, which the majority of them are based on those developed previously for SARS-CoV. The interaction between the spike (S) protein of SARS-CoV-2 and ACE2 on the host cell surface leads to the initiation of SARS-CoV-2 infection. S protein, which is the main inducer of neutralizing antibodies, has been targeted by most of these strategies. Vaccines that induce an immune response against the S protein to inhibit its binding with the host ACE2 receptor, can be considered as effective vaccines against SARS-CoV-2. Here, we aimed to review frontier therapeutics and vaccination strategies for SARS-CoV-2 (COVID-19).
Identifiants
pubmed: 34268202
doi: 10.18502/ijph.v49iS1.3666
pii: IJPH-49-18
pmc: PMC8266011
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
18-29Informations de copyright
Copyright © 2020 Sheikhshahrokh et al. Published by Tehran University of Medical Sciences.
Déclaration de conflit d'intérêts
Conflict of interest The authors declare that there is no conflict of interest.
Références
PLoS One. 2015 Dec 07;10(12):e0144475
pubmed: 26641892
Biosci Trends. 2020 Mar 16;14(1):69-71
pubmed: 31996494
Emerg Microbes Infect. 2018 Mar 21;7(1):41
pubmed: 29568066
Virus Res. 2020 Jan 15;276:197834
pubmed: 31816342
Viruses. 2020 Jan 20;12(1):
pubmed: 31968702
Vaccine. 2014 May 30;32(26):3169-3174
pubmed: 24736006
Chembiochem. 2020 Mar 2;21(5):730-738
pubmed: 32022370
Bull World Health Organ. 2017 Mar 1;95(3):235-237
pubmed: 28250538
J Pharm Sci. 2017 Aug;106(8):1961-1970
pubmed: 28456726
J Med Virol. 2020 May;92(5):479-490
pubmed: 32052466
Emerg Infect Dis. 2005 Jul;11(7):1016-20
pubmed: 16022774
J Infect. 2005 Oct;51(3):263-5
pubmed: 16045996
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
J Immunol Res. 2019 Apr 7;2019:6491738
pubmed: 31089478
Emerg Microbes Infect. 2020 Dec;9(1):275-277
pubmed: 32005086
Nat Biotechnol. 2007 Dec;25(12):1421-34
pubmed: 18066039
Oncotarget. 2017 Feb 7;8(6):9053-9066
pubmed: 28118607
Emerg Microbes Infect. 2019;8(1):516-530
pubmed: 30938227
Nature. 2013 Aug 8;500(7461):227-31
pubmed: 23831647
Virus Res. 2014 Dec 19;194:200-10
pubmed: 25451066
PLoS One. 2019 Jul 22;14(7):e0220196
pubmed: 31329652
Viruses. 2020 Feb 10;12(2):
pubmed: 32050635
Nature. 2015 Jun 25;522(7557):487-91
pubmed: 25855300
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Nat Rev Microbiol. 2009 Mar;7(3):226-36
pubmed: 19198616
J Med Virol. 2020 Apr;92(4):433-440
pubmed: 31967321
Annu Rev Virol. 2016 Sep 29;3(1):237-261
pubmed: 27578435
Springerplus. 2015 Nov 19;4:709
pubmed: 26618098
Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9
pubmed: 15210961
Microbes Infect. 2020 Mar;22(2):74-79
pubmed: 32017984
Curr Trop Med Rep. 2020 Mar 3;:1-4
pubmed: 32219057
Hum Vaccin Immunother. 2014;10(3):648-58
pubmed: 24355931
Expert Rev Vaccines. 2012 Dec;11(12):1405-13
pubmed: 23252385
J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S41-52
pubmed: 20176268
Science. 2020 Jan 31;367(6477):492-493
pubmed: 32001631
N Engl J Med. 2016 Oct 13;375(15):1448-1456
pubmed: 27732819
Adv Virus Res. 2011;81:85-164
pubmed: 22094080
Nat Rev Immunol. 2005 Dec;5(12):917-27
pubmed: 16322745
Expert Opin Ther Targets. 2017 Feb;21(2):131-143
pubmed: 27936982
Pathogens. 2020 Feb 22;9(2):
pubmed: 32098302
Nat Rev Microbiol. 2013 Dec;11(12):836-48
pubmed: 24217413
J Clin Microbiol. 2005 Nov;43(11):5452-6
pubmed: 16272469
Antiviral Res. 2017 Jan;137:82-92
pubmed: 27840203
Front Plant Sci. 2016 Feb 05;7:54
pubmed: 26904039
Nat Rev Microbiol. 2019 Mar;17(3):181-192
pubmed: 30531947
Viruses. 2019 Jan 14;11(1):
pubmed: 30646565
Am J Respir Crit Care Med. 2020 Feb 15;201(4):P7-P8
pubmed: 32004066
J Infect Dis. 1999 Feb;179 Suppl 1:S18-23
pubmed: 9988160
Curr Opin Biotechnol. 2020 Feb;61:110-115
pubmed: 31816585
J Clin Med. 2020 Feb 26;9(3):
pubmed: 32110875
Rev Med Virol. 2012 Jan;22(1):2-17
pubmed: 21905149
IEEE/ACM Trans Comput Biol Bioinform. 2018 Jul-Aug;15(4):1344-1350
pubmed: 28574363
J Virol. 2005 May;79(10):5900-6
pubmed: 15857975
Sci China Life Sci. 2017 Dec;60(12):1399-1402
pubmed: 29134417
Virus Res. 2020 Mar;278:197863
pubmed: 31945421
J Med Virol. 2020 May;92(5):495-500
pubmed: 32022276
Nature. 2004 Apr 1;428(6982):561-4
pubmed: 15024391
Drug Discov Today. 2020 Apr;25(4):668-688
pubmed: 32006468
Viruses. 2019 Jan 17;11(1):
pubmed: 30658390